Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Activating GCN2 and subsequently the Unfolded Protein Response with the small oral molecule NXP800 delays tumor growth in osteosarcoma.

  PMID 41644942 · PMC12895007 · Cell death discovery · 2026 · 7 claims · 13 setups

  Full-text index only

  NXP800 decreases viability of osteosarcoma cell lines by blocking proliferation and inducing apoptosis

  mnng gcn2-gst nmri crystal clonogenic cycle

• MafB is a conserved transcriptional regulator of macrophage development and functional identity across tissues and species.

  PMID 41759510 · PMC7618887 · Immunity · 2026 · 8 claims · 8 setups

  Full-text index only

  MafB is required for full differentiation of bone-marrow-derived macrophages (BMDMs) in vitro and for development of most RTMs in vivo

  bmdms peritoneal rtms irradiated bulk hashtag-barcoded intracellular

• FOXM1 inhibitor, RCM‑1, enhances venetoclax mediated apoptosis through downregulation of ATP2B4 in rhabdomyosarcoma.

  PMID 41789627 · PMC12987556 · International journal of oncology · 2026 · 8 claims · 8 setups

  Has reproduction · 10

  Combination therapy of RCM-1 and venetoclax inhibits RMS tumor growth more efficiently than venetoclax alone in an animal model by decreasing proliferation and inducing apoptosis

  rms injected muscle cck-8 caspase subcutaneous

• VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING.

  PMID 41820368 · PMC13121600 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  CBFB (CBF-β) is a synthetic lethal interactor of VHL in ccRCC cell lines

  786o ccrcc tcga genome-wide competitive immunoblot

• Leveraging the germ layer development patterns to predict prognosis and identify MEST as a novel therapeutic target in glioma.

  PMID 41501725 · PMC12870398 · Cancer cell international · 2026 · 7 claims · 8 setups

  Full-text index only

  MEST is a key oncogenic GLD-related gene and a novel therapeutic target in glioma, identified via a machine learning feature selection framework

  bulk single-cell tcga glioma gsva aucell machine